Aug 13, 2026 04:15PM
Aug 3, 2026 08:30AM
Aug 3, 2026 08:30AM
Jul 21, 2026 08:03AM
Jul 21, 2026 08:00AM
Jul 13, 2026 09:01AM
Jul 13, 2026 09:00AM Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
Jun 30, 2026 08:00PM
Jun 30, 2026 08:00PM
Jun 24, 2026 08:01AM
Jun 24, 2026 08:00AM
Jun 18, 2026 09:01AM
Jun 18, 2026 09:00AM
Jun 15, 2026 08:30AM Cadrenal Therapeutics plans phase 2a trial for kidney injury prevention
Jun 15, 2026 08:30AM
Jun 3, 2026 09:02AM
Jun 3, 2026 09:00AM
May 19, 2026 04:30PM
May 7, 2026 08:30AM
May 7, 2026 08:30AM
Apr 30, 2026 08:30AM Cadrenal receives FDA guidance for phase 3 trial of HIT treatment
Apr 30, 2026 08:30AM
Mar 31, 2026 08:45AM
Mar 31, 2026 08:45AM
Mar 12, 2026 08:00AM
Mar 2, 2026 08:01AM
Mar 2, 2026 08:00AM
Feb 24, 2026 08:30AM Cadrenal Therapeutics reports phase 2 trial results for HIT treatment
Feb 24, 2026 08:30AM
Jan 12, 2026 08:02AM
Jan 12, 2026 08:00AM
Dec 11, 2025 08:05AM
Dec 11, 2025 08:05AM
Aug 5, 2025 06:01AM
Aug 5, 2025 06:00AM Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
May 8, 2025 08:00AM
Mar 13, 2025 04:05PM
Jan 9, 2025 08:44AM
Dec 31, 2024 08:00AM
Nov 12, 2024 09:00AM
Nov 7, 2024 09:00AM
Aug 22, 2024 09:03AM Cadrenal Therapeutics (CVKD) Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
Aug 22, 2024 09:00AM
Aug 20, 2024 09:00AM
Aug 14, 2024 09:00AM
Aug 7, 2024 04:05PM
Aug 6, 2024 09:00AM
Jul 17, 2024 09:00AM
Jun 11, 2024 04:15PM Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024
Jun 3, 2024 09:00AM

330,009 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All